Received Aug 22, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (RECOMBIVAX HB) | MERCK & CO. INC. | UNK | — | — |
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
No additional AE; HCP states patient received 3 dose of TWINRIX "(1st dose on 11/2024, 2nd on 1/6/2025 and 3rd on 2/6/2025") as well as a dose of RECOMBIVAX on 7/3/2025.; This spontaneous report was received from a pharmacist regarding a 58-year-old female patient. The patient's medical history, concurrent conditions, and concomitant therapies were not reported. On an unknown date in November 2024, the patient was vaccinated with the first dose of Hepatitis a vaccine inact (+) Hepatitis b vaccine rHBsAg (yeast) (TWINRIX) 1 dosage form, administered as vaccination (strength, dose, vaccination scheme, route of administration, anatomical site of injection, lot number, and expiration date were not reported). On 06-JAN-2025, the patient was vaccinated with the second dose of Hepatitis a vaccine inact (+) Hepatitis b vaccine rHBsAg (yeast) (TWINRIX) 1 dosage form, administered as vaccination (strength, dose, vaccination scheme, route of administration, anatomical site of injection, lot number, and expiration date were not reported). On 06-FEB-2025, the patient was vaccinated with the third dose of Hepatitis a vaccine inact (+) Hepatitis b vaccine rHBsAg (yeast) (TWINRIX) 1 dosage form, administered as vaccination (strength, dose, vaccination scheme, route of administration, anatomical site of injection, lot number, and expiration date were not reported). On 03-JUL-2025, the patient was vaccinated with a dose of Hepatitis B Vaccine (Recombinant) (RECOMBIVAX HB), 1 dosage form, administered as vaccination (strength, dose, vaccination scheme, route of administration, anatomical site of injection, lot number, and expiration date were not reported) (Extra dose administered). The reporter is planning to administer dose of Hepatitis A Vaccine, Inactivated (VAQTA) due to variation from approved Hepatitis a vaccine inact (+) Hepatitis b vaccine rHBsAg (yeast) (TWINRIX) vaccination schedule. No additional adverse events were reported.